Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models

We have investigated novel vaccine strategies against severe acute respiratory syndrome (SARS) CoV using cDNA constructs encoding the structural antigens: (S), (M), (E), or (N) protein, derived from SARS CoV. PBL from healthy human volunteers were administered i.p. into IL-2 receptor γ-chain disrupt...

Descripción completa

Detalles Bibliográficos
Autores principales: Okada, Masaji, Okuno, Yoshinobu, Hashimoto, Satomi, Kita, Yoko, Kanamaru, Noriko, Nishida, Yasuko, Tsunai, Yoshie, Inoue, Ruriko, Nakatani, Hitoshi, Fukamizu, Reiko, Namie, Yumi, Yamada, Junko, Takao, Kyoko, Asai, Ritsuko, Asaki, Ryoko, Kase, Tetsuo, Takemoto, Yuji, Yoshida, Shigeto, Peiris, J.S.M., Chen, Pei-Jer, Yamamoto, Naoki, Nomura, Tatsuji, Ishida, Isao, Morikawa, Shigeru, Tashiro, Masato, Sakatani, Mitsunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2007
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115525/
https://www.ncbi.nlm.nih.gov/pubmed/17289225
http://dx.doi.org/10.1016/j.vaccine.2007.01.032
Descripción
Sumario:We have investigated novel vaccine strategies against severe acute respiratory syndrome (SARS) CoV using cDNA constructs encoding the structural antigens: (S), (M), (E), or (N) protein, derived from SARS CoV. PBL from healthy human volunteers were administered i.p. into IL-2 receptor γ-chain disrupted SCID mice, and SCID-PBL/hu mice were constructed. These mice can be used to analyze the human immune response in vivo. SARS M DNA vaccine and N DNA vaccine induced human CTL specific for SARS CoV antigens. Alternatively, SARS M DNA vaccines inducing human neutralizing antibodies and human monoclonal antibodies against SARS CoV are now being developed. These results show that these vaccines can induce virus-specific immune responses and should provide a useful tool for development of protective and therapeutic vaccines.

Ejemplares similares